Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y3ME
|
|||
| Former ID |
DAP000062
|
|||
| Drug Name |
Oxaliplatin
|
|||
| Synonyms |
Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Approved | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C8H14N2O4Pt
|
|||
| Canonical SMILES |
C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
|
|||
| InChI |
1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1
|
|||
| InChIKey |
DRMCATBEKSVAPL-BNTLRKBRSA-N
|
|||
| CAS Number |
CAS 61825-94-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7848852, 14854529, 14903423, 24173438, 45633994, 57373686, 78790585, 125309438, 127301221, 127301222, 127301223, 127301224, 127301225, 127301226, 127301227, 127301228, 127301229, 127301230, 127301231, 127301232, 127301233, 127301234, 127301235, 127301236, 127301237, 127301238, 127301239, 127301240, 127301241, 127301242, 127301243, 127301244, 127301245, 127301246, 135684119, 137001870, 152059544, 162036207, 164196639, 174477519, 226396770, 251885690, 252156659, 252316548
|
|||
| ADReCS Drug ID | BADD_D01633 | |||
| SuperDrug ATC ID |
L01XA03
|
|||
| SuperDrug CAS ID |
cas=061825943
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [3], [4] | |||
| Metabolic Effect | Increase activity | |||
| Description | Oxaliplatin can be metabolized by gut microbiota, which results in the increase of the drug's activity. | |||
| Studied Microbe: Gut microbiota unspecific | [5] | |||
| Metabolic Effect | Increase toxicity | |||
| Description | Oxaliplatin can be metabolized by gut microbiota, which results in the increase of the drug's toxicity. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human Deoxyribonucleic acid (hDNA) | Target Info | Modulator | [6] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7433). | |||
| REF 2 | The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. Gan To Kagaku Ryoho. 2009 May;36(5):797-801. | |||
| REF 3 | Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome. 2018 May 22;6(1):92. | |||
| REF 4 | Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep. 2015 Sep 29;5:14554. | |||
| REF 5 | Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions. Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1043-1055. | |||
| REF 6 | Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.